Spots Global Cancer Trial Database for Dalpiciclib in HR+/HER2- ABC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dalpiciclib in HR+/HER2- ABC
Official Title: Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
Study ID: NCT06301438
Conditions
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, , China
Contact Details
Name: Wenjin Yin
Affiliation: Renji Hospital, School of Medicine, Shanghai Jiaotong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
